By Sneha S K and Bageshri Banerjee

(Reuters) -The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals’ drug to treat a rare hormonal disorder on Thursday, making it the first once-daily oral pill available for patients in the country.

The drug, Palsonify, chemically known as paltusotine, was approved to treat acromegaly, a rare condition in which the pituitary gland in the brain produces excess growth hormone, causing the bones, organs and other tissues to grow bigger, caused due to a tumor on the pituitary gland.

Treatment options for acromegaly include surgery to remove pituitary tumors, radiation therapy and medications such as somatostatin analogs that reduce growth hormone levels and may shrink tumors.

The current standard-of-care involves monthly injections of dr

See Full Page